These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 20970976)
21. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Lee JH; Lee YK; Kim EK; Kim TH; Huh JW; Kim WJ; Lee JH; Lee SM; Lee S; Lim SY; Shin TR; Yoon HI; Sheen SS; Kim N; Seo JB; Oh YM; Lee SD Respir Med; 2010 Apr; 104(4):542-9. PubMed ID: 19926461 [TBL] [Abstract][Full Text] [Related]
22. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Duffy N; Walker P; Diamantea F; Calverley PM; Davies L Thorax; 2005 Sep; 60(9):713-7. PubMed ID: 15939732 [TBL] [Abstract][Full Text] [Related]
23. [Comparison of lung volume response with airflow response to bronchodilator in patients with chronic obstructive pulmonary disease]. Zhang FQ; Zheng JP; Wang JH; Lu WB; Wu RX; Li XS; Xian QZ; Gao Y; Jiang M Zhonghua Jie He He Hu Xi Za Zhi; 2010 Feb; 33(2):109-13. PubMed ID: 20367950 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054 [TBL] [Abstract][Full Text] [Related]
25. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. Van de Maele B; Fabbri LM; Martin C; Horton R; Dolker M; Overend T COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630 [TBL] [Abstract][Full Text] [Related]
26. Modulation of operational lung volumes with the use of salbutamol in COPD patients accomplishing upper limbs exercise tests. Porto EF; Castro AA; Nascimento O; Oliveira RC; Cardoso F; Jardim JR Respir Med; 2009 Feb; 103(2):251-7. PubMed ID: 18930646 [TBL] [Abstract][Full Text] [Related]
27. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403 [TBL] [Abstract][Full Text] [Related]
28. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. Hanrahan JP; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Baumgartner RA COPD; 2008 Feb; 5(1):25-34. PubMed ID: 18259972 [TBL] [Abstract][Full Text] [Related]
29. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P; Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985 [TBL] [Abstract][Full Text] [Related]
30. Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: results from the DIMCA programme. den Otter JJ; van Schayck CP; Folgering HT; van den Boom G; Akkermans RP; van Weel C Eur J Gen Pract; 2007; 13(2):89-91. PubMed ID: 17534745 [TBL] [Abstract][Full Text] [Related]
31. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242 [TBL] [Abstract][Full Text] [Related]
32. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. Papadopoulos NG; Philip G; Giezek H; Watkins M; Smugar SS; Polos PG J Asthma; 2009 May; 46(4):413-20. PubMed ID: 19484680 [TBL] [Abstract][Full Text] [Related]
34. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Decramer M; Maltais F; Feldman G; Brooks J; Harris S; Mehta R; Crater G Respir Physiol Neurobiol; 2013 Jan; 185(2):393-9. PubMed ID: 23026438 [TBL] [Abstract][Full Text] [Related]
35. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Vestbo J; Tan L; Atkinson G; Ward J; Eur Respir J; 2009 May; 33(5):1039-44. PubMed ID: 19213793 [TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Watz H; Mistry SJ; Lazaar AL; Pulm Pharmacol Ther; 2013 Oct; 26(5):588-95. PubMed ID: 23701917 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Woodruff PG; Wolff M; Hohlfeld JM; Krug N; Dransfield MT; Sutherland ER; Criner GJ; Kim V; Prasse A; Nivens MC; Tetzlaff K; Heilker R; Fahy JV Am J Respir Crit Care Med; 2010 Mar; 181(5):438-45. PubMed ID: 20007923 [TBL] [Abstract][Full Text] [Related]
38. A randomized, placebo-controlled trial of bronchodilators for bronchoscopy in patients with COPD. Stolz D; Pollak V; Chhajed PN; Gysin C; Pflimlin E; Tamm M Chest; 2007 Mar; 131(3):765-772. PubMed ID: 17356091 [TBL] [Abstract][Full Text] [Related]
39. Paid employment in subjects with and without chronic obstructive pulmonary disease in five Latin American cities: the PLATINO study. Montes de Oca M; Halbert RJ; Talamo C; Perez-Padilla R; Lopez MV; Muiño A; Jardim JR; Valdivia G; Pertuzé J; Moreno D; Menezes AM; Int J Tuberc Lung Dis; 2011 Sep; 15(9):1259-64, i-iii. PubMed ID: 21943855 [TBL] [Abstract][Full Text] [Related]
40. Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study. de Matos Cavalcante AG; de Bruin PF; de Bruin VM; Nunes DM; Pereira ED; Cavalcante MM; Andrade GM J Pineal Res; 2012 Oct; 53(3):238-44. PubMed ID: 22507631 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]